Publication Name	World Journal of Gastroenterology
Manuscript ID	41380
Country	Spain

Category	Gastroenterology & Hepatology
Manuscript Type	Observational Study
Article Title	Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, Belen Maldonado Perez, Antonio Benitez Roldan, Raul Perea Amarillo, Vicente Merino Bohorquez, Miguel Angel Calleja, Angel Caunedo Alvarez and Angel Vilches Arenas
Funding Agency and Grant Number
Corresponding Author	Federico Argüelles-Arias, PhD, Doctor, Professor, Department of Gastroenterology, University Hospital Virgen Macarena, Dr. Fedriani 3, seville 41007, Spain. farguelles@telefonica.net
Key Words	Crohn’s disease; Ulcerative colitis; CT-P13; Inflammatory bowel disease; Biosimilar agent; Infliximab original; Efficacy
Core Tip	Although not strictly necessary, there are few studies comparing efficacy and safety of the switch from infliximab original (Remicade®) to infliximab biosimilar CT-P13 vs the maintenance of the original infliximab. For this reason, we presented a comparative study with the original infliximab. Our observational study demonstrates the real-life clinical results of efficacy and safety of inflixi­mab original and the efficacy and safety after switching from original infliximab to infliximab biosimilar CT-P13 at the 12 mo follow-up. Our results demonstrate there is no statistical difference in remission rate, secondary loss of response or adverse events between both therapies.
Citation	Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldán A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296

Received	2018-08-29 02:03
Peer-Review Started	2018-08-29 07:12
To Make the First Decision	2018-10-08 02:56
Return for Revision	2018-10-14 07:09
Revised	2018-11-18 19:01
Second Decision	2018-12-06 10:04
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-12-07 03:32
Articles in Press	2018-12-07 03:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-12-12 03:47

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com